ATE415148T1 - Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid - Google Patents

Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid

Info

Publication number
ATE415148T1
ATE415148T1 AT05795965T AT05795965T ATE415148T1 AT E415148 T1 ATE415148 T1 AT E415148T1 AT 05795965 T AT05795965 T AT 05795965T AT 05795965 T AT05795965 T AT 05795965T AT E415148 T1 ATE415148 T1 AT E415148T1
Authority
AT
Austria
Prior art keywords
donepezil hydrochloride
pharmaceutical composition
solid pharmaceutical
composition containing
containing donepezil
Prior art date
Application number
AT05795965T
Other languages
English (en)
Inventor
Miha Vrbinc
Berta Kotar-Jordan
Rok Zupet
Matej Smrkolj
Original Assignee
Krka Tovarna Zdravil D D Novo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35464350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE415148(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka Tovarna Zdravil D D Novo filed Critical Krka Tovarna Zdravil D D Novo
Application granted granted Critical
Publication of ATE415148T1 publication Critical patent/ATE415148T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Glanulating (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05795965T 2004-10-19 2005-10-19 Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid ATE415148T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004051055 2004-10-19

Publications (1)

Publication Number Publication Date
ATE415148T1 true ATE415148T1 (de) 2008-12-15

Family

ID=35464350

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05795965T ATE415148T1 (de) 2004-10-19 2005-10-19 Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid

Country Status (19)

Country Link
US (3) US20090130205A9 (de)
EP (3) EP2283811A1 (de)
JP (1) JP2008517022A (de)
AT (1) ATE415148T1 (de)
CA (1) CA2584547C (de)
CY (1) CY1109956T1 (de)
DE (1) DE602005011326D1 (de)
DK (1) DK1811957T3 (de)
EA (1) EA012220B1 (de)
ES (1) ES2317313T3 (de)
HR (1) HRP20090104T3 (de)
NO (1) NO20072494L (de)
PL (1) PL1811957T3 (de)
PT (1) PT1811957E (de)
RS (1) RS51271B (de)
SI (1) SI1811957T1 (de)
UA (1) UA83152C2 (de)
WO (1) WO2006045512A1 (de)
ZA (1) ZA200704023B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0515803D0 (en) * 2005-07-30 2005-09-07 Pliva Hrvatska D O O Intermediate compounds
DE102005060377A1 (de) * 2005-12-16 2007-06-21 Ratiopharm Gmbh Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung
EP2037918A2 (de) * 2006-05-15 2009-03-25 Acadia Pharmaceuticals Inc. Pharmazeutische pimavanserin-formulierungen
GB0614586D0 (en) * 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
AU2008207864B2 (en) * 2007-01-24 2013-07-11 Cook Biotech Incorporated Biofilm-inhibiting medical products
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
DE102007037932A1 (de) 2007-08-11 2009-02-12 Alfred E. Tiefenbacher Gmbh & Co.Kg Donepezilhydrochlorid in amorpher Form enthaltende Tablette
DE102009041839A1 (de) * 2009-09-18 2011-03-24 Dolorgiet Gmbh & Co. Kg Donepezil-haltige Tabletten
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2366378A1 (de) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Donepezilformulierungen mit verzögerter Freisetzung
DE102010010998A1 (de) * 2010-03-10 2011-09-15 Stada Arzneimittel Ag Feste pharmazeutische Zusammensetzung, umfassend Donepezil-Hydrochlorid der kristallinen polymorphen Form I
WO2012016708A1 (en) 2010-08-06 2012-02-09 Ratiopharm Gmbh Oral dosage form comprising dimebolin and donepezil
CA2818068C (en) * 2010-11-30 2019-06-11 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
EP2502620A1 (de) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Feste pharmazeutische Zusammensetzung mit Donepezil
MX383665B (es) 2014-02-04 2025-03-14 Forest Laboratories Holdings Ltd Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
CN114272219B (zh) * 2021-12-30 2023-11-10 江苏豪森药业集团有限公司 一种盐酸多奈哌齐片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
WO1997046526A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
CA2252806C (en) 1996-06-07 2005-11-22 Eisai Co., Ltd. Polymorphs of donepezil hydrochloride and process for production
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
CA2279846C (en) * 1997-02-07 2008-06-03 Princeton University Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
WO1999042599A1 (en) * 1998-02-19 1999-08-26 Sapporo Breweries Ltd. Isolated and purified nucleic acids comprising a gene specifically expressed in hop glands
ES2211056T3 (es) * 1999-03-31 2004-07-01 Eisai Co., Ltd. Composiciones estabilizadas que contienen farmacos nootropicos.
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ATE437632T1 (de) * 2000-03-01 2009-08-15 Eisai R&D Man Co Ltd Schnellzerfallende polyvinylhaltige tablette
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
IN192180B (de) * 2001-09-28 2004-03-06 Ranbaxy Lab
TWI231760B (en) * 2001-12-20 2005-05-01 Chugai Pharmaceutical Co Ltd Coated lozenge and manufacturing method thereof
SI21223A (sl) * 2002-06-19 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom
IL150509A (en) 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
AU2003280324A1 (en) * 2002-11-26 2004-06-18 Alk-Abello A/S Pharmaceutical allergen product
AU2003245029A1 (en) * 2003-04-16 2004-11-04 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040265372A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics

Also Published As

Publication number Publication date
DE602005011326D1 (de) 2009-01-08
UA83152C2 (ru) 2008-06-10
PL1811957T3 (pl) 2009-05-29
DK1811957T3 (da) 2009-03-30
US20090130205A9 (en) 2009-05-21
PT1811957E (pt) 2009-01-27
EP2283811A1 (de) 2011-02-16
HRP20090104T3 (hr) 2009-03-31
NO20072494L (no) 2007-07-02
CY1109956T1 (el) 2014-09-10
JP2008517022A (ja) 2008-05-22
US20120283291A1 (en) 2012-11-08
RS51271B (sr) 2010-12-31
ES2317313T3 (es) 2009-04-16
EP1811957B1 (de) 2008-11-26
WO2006045512A1 (en) 2006-05-04
EA012220B1 (ru) 2009-08-28
CA2584547A1 (en) 2006-05-04
SI1811957T1 (sl) 2009-04-30
EP2039349A1 (de) 2009-03-25
US20100317694A1 (en) 2010-12-16
EP1811957A1 (de) 2007-08-01
ZA200704023B (en) 2008-04-30
US20080063705A1 (en) 2008-03-13
CA2584547C (en) 2014-07-08
EA200700673A1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
NO2014009I2 (no) Forbindelser, farmasøytiske sammensetninger og anvendelser derav, samt fremgangsmåte for å fremstille nevnte forbindelser
ATE415148T1 (de) Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid
ATE454138T1 (de) Tablette mit modifizierter freisetzung von bupropion hydrochlorid
HUP0303313D0 (en) Transdermal pharmaceutical compositions
ZA200708580B (en) Composition containing anti-dementia drug
IL179933A0 (en) Pharmaceutical compositions containing proteosome based compositions
IL181827A0 (en) Donepezil salts suitable for the preparation of pharmaceutical compositions
ZA200700685B (en) Novel piperidine derivative for the treatment of depression
HU0301154D0 (en) Pharmaceutical composition
GB0300427D0 (en) Pharmaceutical composition
PL394600A1 (pl) Związek winyloazacykloalkanowy, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
EP1699458A4 (de) Pharmazeutische zusammensetzung
IL183163A0 (en) Sulfonamido-macrocycles as tie2 inhibitors and the salts thereof, a pharmaceutical composition comprising these compounds, the method of preparing and the use thereof
GB0317663D0 (en) Pharmaceutical composition
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
GB2411355B (en) Pharmaceutical composition
GB0300885D0 (en) Pharmaceutical composition
IL157398A0 (en) Pharmaceutical compositions comprising ccr5 antagonists
GB0425255D0 (en) Pharmaceutical composition
GB0306933D0 (en) Pharmaceutical composition
ZA200701931B (en) Pharmaceutical composition
ATE489943T1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivate
GB0307869D0 (en) Pharmaceutical composition
ITMI20030826A1 (it) Composizione farmaceutica contenente interferone per il
GB0307867D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1811957

Country of ref document: EP